PDL BioPharma (PDLI) Sees Q2 Revenues of $125M
More News related to PDLI
- PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- PDL BioPharma (PDLI) Reports Mixed Q3 Results; Narrows FY09 Sales Guidance
- PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction
- PDL BioPharma Announces Third Quarter 2009 Financial Results
More News related to Guidance
- Moody's Suggests AIG (AIG) Could Repay the U.S.
- Might Cisco (CSCO) and EMC (EMC) Look to Merge, or Simply Stay Friends With Benefits?
- Research In Motion (RIMM) Blows-Off Downgrade, Shares up 3% On Renewed Takeover Talk
- Sprint and Others Could Pump Another $1.5B Into Clearwire (CLWR)
PDL BioPharma, Inc. (Nasdaq: PDLI) announced revenue guidance for the second quarter ended June 30, 2009 of approximately $125 million, as compared with $106 million for the second quarter of 2008. The Wall Street consensus is $114.6 million.
The increase is due primarily to royalty revenues driven by higher product sales of Avastin(R), and Lucentis(R), which are marketed by Genentech, and sales of Tysabri(R), which is marketed by Elan.
Related Categories
GuidanceStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
